Follow on Google News Industry News News By Location Country(s) Industry News
Follow on Google News | Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015)Renub Research has announced the addition of the Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015)
By: Renub Research Schizophrenia is a mental disorder characterized by disintegration of thought processes and of emotional responsiveness. It most commonly manifests as auditory hallucinations, paranoid or bizarre delusions, or disorganized speech and thinking, or lack of concentration and motivation and it is accompanied by significant social or occupational dysfunction. However with proper medication this disease can be contained to a great extent and Schizophrenia patients can lead a normal healthy life style. At present lot of drugs for Schizophrenia are available in the market. From the introduction of Clozapine in 1991.Since, 1960, the first atypical antipsychotic to treat schizophrenia, the growth of this class has been rapid. Zyprexa, Seroquel, Risperdal, Abilify, Geodon are the blockbuster drug which has changed the dynamics of the schizophrenia market. But the major worry for the manufactures of these drugs is that by 2011 and 2012 almost all the major blockbuster drugs are going off-patent. However, depot formulation is the emerging segment which has long term chances of success. The pipeline drug like Lurasidone, Staccato, Cariprazine, Pimavanserin have the comparable efficacy and a similar mechanism of action to that of the existing brands which will enter the market by 2011. Report Details Global Schizophrenia Prevalence, Companies Analysis & Drugs Forecast (2010 – 2015)” report published by Renub Research provides an in-depth analysis of the past, present and future prospects. The report has been researched at source globally and features latest available data covering: • Global Schizophrenia Market has been covered from 2004-2019 • Global Schizophrenia patients in 7 countries • Top 10 Schizophrenia Drug Brands (Zyprexa, Seroquel, Risperdal, Abilify, Geodon, Lonasen, Serdolect, Invega, Fanapt, Saphris) data analysis of Past, Present and Future Market • Top 3 Schizophrenia Depot Formulations Brands (Risperdal Consta, Invega Sustenna, Relprevv) data analysis of Past, Present and Future Market • Pipeline Developmental Agents (Lurasidone, Staccato, Cariprazine, Pimavanserin) • Key Companies Strengths and Weakness analysis in Global Schizophrenia Research Highlights • The prevalence of Schizophrenia in United States is expected to reach nearly 4 Million by 2020 • From 2012 onwards Schizophrenia market is expected to show a decline • Zyprexa is the most successful product in the history of neuroscience • Abilify hit blockbuster sales in 2006 and it is anticipated that sales will cross US$ 2.5 Billion by 2014. • Risperdal Consta is the blockbuster injectable form of medicines and predicted that the sale will cross US$ 2 Billion by 2014 • Lurasidone, Staccato, Cariprazine, Pimavanserin are the pipepline drug which will be launched by 2011 Data Sources Information and data in this report has been collected from various printable and non-printable sources like Trade Journals, White papers, Online paid databases, News websites, Government Agencies, Magazines, Newspapers and Trade associations. Contacts Renub Research Ankit Mishra Relationship Manager Email: info@renub.com Phone: +91-120-4219- +1-678-3020- For more information visit: http://www.renub.com/ Related Reports: http://www.renub.com/ http://www.renub.com/ http://www.renub.com/ # # # Renub Research is a leading Market Research and Information Analysis Company with centers at Noida, India and Roswell, USA. We have more than 7 years of experience especially in international Business-to- Our core team is comprised of an experienced people holding graduate, post graduate and Ph.D. degrees in Finance, Marketing, Human Resource, Bio-Technology, Medicine, Information Technology, Environmental Science and many more. Our research help make the business decisions: on strategy, organization, operations, technology, mergers & acquisitions etc. End
|
| ||||||||||||||||||||||||||||||||||||||||||||
Account Phone Number